Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021
Rhea-AI Summary
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) will host a conference call and live webcast on February 25, 2021, at 8:00 a.m. ET to discuss its fourth quarter and year-end 2020 financial results and business highlights. The event will be available for replay on their website shortly after it concludes. Agios focuses on developing innovative medicines for cancer and genetically defined diseases, with a robust pipeline and two approved oncology agents. For further details, visit www.agios.com.
Positive
- Focused on novel investigational medicines for hematology, solid tumors, and genetically defined diseases.
- Possesses two approved oncology precision medicines.
- Active research pipeline with multiple first-in-class investigational therapies.
Negative
- None.
News Market Reaction – AGIO
In the trading session that priced this news, AGIO gained 1.45%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company will host a conference call and live webcast on Thursday, February 25, 2021 at 8:00 a.m. ET to report its fourth quarter and year end 2020 financial results and other business highlights.
A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and referring to conference ID 8442238. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and genetically defined diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. For more information, please visit the company's website at www.agios.com.
Contacts
Investors:
Holly Manning, 617-844-6630
Director, Investor Relations
Holly.Manning@agios.com
Media:
Jessica Rennekamp, 857-209-3286
Associate Director, Corporate Communications
Jessica.Rennekamp@agios.com